Browse by Section 100 Item List

Highly Specialised Drugs Program (Community Access)

From 1 July 2015, the HSD community access arrangements better align existing HSD programme arrangements with current clinical practice and models of care, through improvements to the way clozapine for the treatment of schizophrenia (maintenance therapy only), HIV antiretroviral medicines and hepatitis B medicines are prescribed, dispensed and accessed under the s100 HSDs Programme.  These changes are known as ‘HSD Community Access’.

These arrangements remove the requirement for patients and prescribers to be affiliated with a hospital setting.  Patients also have greater choice about where they access their medicines, through either a community pharmacy, or a private or public hospital pharmacy.  Community pharmacists are able to dispense these medicines regardless of where the medicine is prescribed.

Prescriptions for these medicines and any repeats from those prescriptions, written prior to 1 July 2015 will need to be dispensed by a hospital pharmacy in accordance with the previous arrangements.

The remuneration rates for Highly Specialised Drugs dispensed through community pharmacies are aligned to those paid to private hospitals.

Patient eligibility criteria are unchanged.  Patients will continue to pay a patient co-payment which will contribute to the PBS Safety Net Record.

Further information on these arrangements is available in the respective Frequently Asked Questions (FAQs).

  • Legend
  • MPMedical Practitioner
  • NPNurse Practitioner
Prescriber code Item code Name, manner of administration and form & strength Max qty
packs
Max qty
units
No. of
repeats
MPNP 10320E LAMIVUDINElamivudine 10 mg/mL oral liquid, 240 mL 8 8 5
MPNP 10315X LAMIVUDINElamivudine 100 mg tablet, 28 2 56 5
MPNP 10348P LAMIVUDINElamivudine 150 mg tablet, 60 2 120 5
MPNP 10311Q LAMIVUDINElamivudine 300 mg tablet, 30 2 60 5
MPNP 10284G LAMIVUDINE + ZIDOVUDINElamivudine 150 mg + zidovudine 300 mg tablet, 60 2 120 5
MP 11289E LANREOTIDElanreotide 120 mg/0.5 mL injection, 0.5 mL syringe 2 2 5
MP 11736Q LANREOTIDElanreotide 120 mg/0.5 mL injection, 0.5 mL syringe 2 2 5
MP 11315M LANREOTIDElanreotide 60 mg/0.5 mL injection, 0.5 mL syringe 2 2 5
MP 11316N LANREOTIDElanreotide 90 mg/0.5 mL injection, 0.5 mL syringe 2 2 5
MPNP 10285H LOPINAVIR + RITONAVIRlopinavir 100 mg + ritonavir 25 mg tablet, 60 2 120 5
MPNP 10327M LOPINAVIR + RITONAVIRlopinavir 400 mg/5 mL + ritonavir 100 mg/5 mL oral liquid, 60 mL 10 10 5
MPNP 10272P LOPINAVIR + RITONAVIRlopinavir 200 mg + ritonavir 50 mg tablet, 120 2 240 5